Generation of Redirected Engineered Human Chimeric Antigen Receptor (CAR) T Cells

Chimeric antigen receptor (CAR)Chimeric antigen receptor (CAR) T cellT-cell therapy that involves genetic engineeringGenetic engineering a patient’s own immune cells with antigen-specific receptors has shown remarkable efficacy in bloodBlood cancer treatment. Numerous clinical studies with CAR Chimeric antigen receptor (CAR) T cells targeting the bloodBlood cell surface protein CD19 led to the FDA Food and Drug Administration (FDA) ’s first approval of a genetically engineered cell therapy. The process of generating potent CAR Chimeric antigen receptor (CAR) T cells involves several carefully performed manufacturing steps. Here, we describe the generation of redirected engineered human CAR Chimeric antigen receptor (CAR) T cells for preclinical studies starting with the CAR Chimeric antigen receptor (CAR) design, retroviral gene transferGene transfer, detection of CAR Chimeric antigen receptor (CAR) expression, and expansion of transduced T cells.